In vitro synergistic cytotoxic effect of triptolide combined with hydroxycamptothecin on pancreatic cancer cells

American Journal of Chinese Medicine

Volumn 39, Issue 1, 2011, Pages 121-134

  Yang, Su Wen ^a,b   Wang, Wei ^c   Xie, Xin You ^a,b   Zhu, Wan Ping ^c   Li, Fang Qiong ^c  

^a ZHEJIANG UNIVERSITY   (China)

^b Key Laboratory of Medical Molecular Imaging of Zhejiang Province   (China)

^c TONGDE HOSPITAL OF ZHEJIANG PROVINCE   (China)

Author keywords

Caspase; Hydroxycamptothecin; NF B; PANC 1; Triptolide

Indexed keywords

10 HYDROXYCAMPTOTHECIN; CASPASE 3; CASPASE 9; TRANSCRIPTION FACTOR RELA; TRIPTOLIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL VIABILITY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; DITERPENES; DRUG SYNERGISM; EPOXY COMPOUNDS; HUMANS; NF-KAPPA B; PANCREATIC NEOPLASMS; PHENANTHRENES; PHYTOTHERAPY; PLANT EXTRACTS; SIGNAL TRANSDUCTION; TRIPTERYGIUM;

EID: 78751528792     PISSN: 0192415X     EISSN: None     Source Type: Journal    
DOI: 10.1142/S0192415X11008695     Document Type: Article

References (33)

1. Berlin, J.D., P. Catalano, J.P. Thomas, J.W. Kugler, D.G. Haller and A.B. Benson. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trail E2297. J. Clin. Oncol. 20(15): 3270-3275, 2002.
2. Burris, H.A., M.J. Moore, J. Andersen, M.R. Green, M.L. Rothenberg, M.R. Modiano, M.C. Cripps, R.K. Portenoy, A.M. Storniolo, P. Tarassoff, R. Nelson, F.A. Dorr, C.D. Stephens and D.D. Von Hoff. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15(6): 2403-2413, 1997.
3. Chan, E.W., S.C. Cheng, F.W. Sin and Y. Xie. Triptolide induced cytotoxic effects on human promyelocytic leukemia, T cell lymphoma and human hepatocellular carcinoma cell lines. Toxicol. Lett. 122: 81-87, 2001.
4. Chang, W.T., J.J. Kang, K.Y. Lee, K. Wei, E. Anderson, S. Gotmare, J.A. Ross and G.D. Rosen. Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J. Biol. Chem. 276: 2221-2227, 2001.
5. Chen, Y.W., G.J. Lin, Y.P. Chuang, W.T. Chia, D.Y. Hueng, C.K. Lin, S. Nieh and H.K. Sytwu. Triptolide circumvents drug-resistant effect and enhances 5-fluorouracil antitumor effect on KB cells. Anticancer Drugs. 21: 502-513, 2010.
6. Chou, T.C. and P. Talalay. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
7. Fidler, J.M., K. Li, C. Chung, K. Wei, J.A. Ross, M. Gao and G.D. Rosen. PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Mol. Cancer Ther. 2: 855-862, 2003.
8. Heinemann V. Quietzsch D. Gieseler F. Gonnermann M. Schönekäs H. Rost A. Neuhaus H. Haag C. Clemens M. Heinrich B. Vehling-Kaiser U. Fuchs M. Fleckenstein D. Gesierich W. Uthgenannt D. Einsele H. Holstege A. Hinke A. Schalhorn A. Wilkowski R. Randomized Phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer J. Clin. Oncol. 2006 24(24) 3946-3952
9. Herrmann, R., G. Bodoky, T. Ruhstaller, B. Glimelius, E. Bajetta, J. Schüller, P. Saletti, J. Bauer, A. Figer, B. Pestalozzi, C.H. Köhne, W. Mingrone, S.M. Stemmer, K. Tàmas, G.V. Kornek, D. Koeberle, S. Cina, J. Bernhard, D. Dietrich and W. Scheithauer. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized multicenter, Phase III trial of the Swiss Group For Clinical Cancer Research and The Central European Cooperative Oncology Group. J. Clin. Oncol. 25(16): 2212-2217, 2007.
10. Howard, T.J. Pancreatic adenocarcinoma. Curr. Probl. Cancer 20: 281-328, 1996.
11. Ichikawa, H., Y. Nakamura, Y. Kashiwada and B.B. Aggarwal. Anticancer drugs designed by mother nature: ancient drugs but modern targets. Curr. Pharm. Des. 13: 3400-3416, 2007.
12. Jemal, A., R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray and M.J. Thun. Cancer statistics, 2008. CA Cancer J. Clin. 58: 71-96, 2008.
13. Jiang, X.H., B.C. Wong, M.C. Lin, G.H. Zhu, H.F. Kung, S.H. Jiang, D. Yang and S.K. Lam. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factorkappaB activation in gastric cancer cells. Oncogene 20: 8009-8018, 2001.
14. Kang, D.W., J.Y. Lee, D.H. Oh, S.Y. Park, T.M. Woo, M.K. Kim, M.H. Park, Y.H. Jang and S. Min. Triptolide-induced suppression of phospholipase D expression inhibits proliferation of MDAMB- 231 breast cancer cells. Exp. Mol. Med. 41: 678-685, 2009.
15. Karst, A.M., K. Gao, C.C. Nelson and G. Li. Nuclear factor kappaB subunit p50 promotes melanoma angiogenesis by upregulating interleukin-6 expression. Int. J. Cancer 124: 494-501, 2009.
16. Kiviharj, T.M., P.S. Lecane, R.G. Sellers and D.M. Peehl. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin. Cancer Res. 8: 2666-2674, 2002.
17. Kupchan, S.M., W.A. Court, R.G. Dailey, C.J. Gilmore and R.F. Bryan. Triptolide and tripdiolide, novel antileukemic ditepenoid tripoxides from Triterygium wilfordii. J. Am. Chem. Soc. 94: 7194-7195, 1972.
18. Lee, H.J., H.J. Lee, E.O. Lee, J.H. Lee, K.S. Lee, K.H. Kim, S.H. Kim and J. Lu. In vivo anti-cancer activity of Korean Angelica gigas and its major pyranocoumarin decursin. Am. J. Chin. Med. 37: 127-142, 2009.
19. Lee, K.Y., W. Chang, D. Qiu, P.N. Kao and G.D. Rosen. PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J. Biol. Chem. 274(19): 13451-13455, 1999.
20. Lou, Y.J. and J. Jin. Triptolide down-regulates bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells. Leuk. Lymphoma 45: 373-376, 2004.
21. Morris, E.J. and H.M. Geller. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity. J. Cell Biol. 134: 757-770, 1996.
22. Pigneux, A., F.X. Mahon, M. Uhalde, M. Jeanneteau, F. Lacombe, N. Milpied, J. Reiffers and F. Belloc. Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells. Exp. Hematol. 36: 1648-1659, 2008.
23. Qiu, D., G. Zhao, Y. Aoki, L. Shi, A. Uvei, S. Nazarian, J.C. Ng and P.N. Kao. Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-KappaB transcriptional activation. J. Biol. Chem. 274(19): 13443-13450, 1999.
24. Tang, X.Y., Y.Q. Zhu, W.H. Tao, B. Wei and X.L. Lin. Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma. Postgrad. Med. J. 83: 338-343, 2007.
25. Tao, X., J.J. Cai and P.E. Lipsky. The identity of immunosuppressive components of the ethyl acetate extracts and chloroform methanol extract of Tripterygium wilfordii Hook. J. Pharmacol. Exp. Ther. 272: 1305-1312, 1995.
26. Xu, B., X. Guo, S. Mathew, A.L. Armesilla, J. Cassidy, J.L. Darling and W. Wang. Triptolide simultaneously induces reactive oxygen species, inhibits NF-kappaB activity and sensitizes 5-fluorouracil in colorectal cancer cell lines. Cancer Lett. 291: 200-208, 2010.
27. Yang, M., J. Huang, H.Z. Pan and J. Jin. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells. Int. J. Mol. Med. 22: 489-496, 2008.
28. Yang, S. and J. Chen. Triptolide inhibits the growth and metastasis of solid tumors. Mol. Cancer Ther. 2: 65-72, 2003.
29. Yeo, C.J. and J.L. Cameron. Improving results of pancreaticoduodenectomy for pancreatic cancer. World J. Surg. 23: 907-912, 1999.
30. Yinjun, L., J. Jie and W. Yungui. Triptolide inhibits transcription factor NF-kappaB and induces apoptosis of multiple myeloma cells. Leuk. Res. 29: 99-105, 2005.
31. Zhang, C., G.H. Cui, F. Lin, Q.L. Wu and Y. Chen. Inhibitory effect of triptolide on lymph node metastasis in patients with non-hodgkin lymphoma by regulating SDF-1/CXCR4 axis in vitro. Acta. Pharmacol. Sin. 27: 1438-1446, 2006.
32. Zhou, Y.X., Y.L. Huang, Q.N. Xu, M. Ye, C.F. Sun and D. Zhou. Several monomes from Tripterygium wilfordii inhibit proliferation of glioma cells in vitro. Ai Zheng 21: 1106-1108, 2002.
33. Zhu, W., Y. Ou, Y. Li, R. Xiao, M. Shu, Y. Zhou, J. Xie, S. He, P. Qiu and G. Yan. A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappaB pathway. Mol. Pharmacol. 75: 812-819, 2009.